Effective Switch From Twice-Daily Pre-Mixed Insulin 50/50 to Liraglutide to Achieve a Good Glycemic Control in Type 2 Diabetes
Effective Switch From Twice-Daily Pre-Mixed Insulin 50/50 to Liraglutide to Achieve a Good Glycemic Control in Type 2 Diabetes
复制标题
从每日两次预混合胰岛素 50/50 有效转换为利拉鲁肽，以实现 2 型糖尿病的良好血糖控制
DOI：
10.4021//jmc.v2i2.143
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
R. Honda
中科院分区：
文献类型：
--
作者：
H. Yanai;Taro Yoshimi;R. Honda
胰升糖素样肽1(GLP-1)以葡萄糖依赖的方式刺激胰岛β细胞分泌胰岛素。2型糖尿病的治疗策略主要集中在使用GLP-1类似物上。利拉鲁肽是一种人GLP-1的酰化类似物，已于2010年在日本推出。我们将展示一位患有2型糖尿病的70岁女性患者，通过从每天两次预混合胰岛素50/50改为利拉鲁肽，实现了良好的血糖控制。餐前、餐后血糖和血清C-肽水平及每日尿C-肽水平的测定表明，利拉鲁肽改善糖代谢主要不是通过葡萄糖依赖的胰岛素调节作用，而是通过改善胰岛素敏感性。此外，胰高血糖素负荷试验的结果表明，利拉鲁肽降低血糖水平不是通过促进胰岛素分泌，而是通过抑制胰高血糖素介导的肝脏葡萄糖输出。
The glucagon-like peptide 1 (GLP-1) stimulates insulin secretion from pan creatic ? -cells in a glucose-dependent manner. Therapeutic strategies for type 2 diabetes mellitus are focused on the use of GLP-1 analogues. Liraglutide, an acylated analogue of human GLP-1, has been introduced in Japan in 2010. We will show a 70-year-old woman with type 2 diabetes mellitus achieving a good glycemic control by switching from twice-daily pre-mixed insulin 50/50 to liraglutide. Measurements of plasma glucose and serum C-peptide levels before and after each meal ingestion and daily urinary C-peptide levels suggested that liraglutide ameliorates glucose metabolism mainly not by the glucose-dependent insulinotropic effect but by amelioration in insulin sensitivity. Furthermore, results from a glucagon-loading test indicated that liraglutide reduced plasma glucose levels not by enhancing insulin secretion but by suppressing glucagon-mediated hepatic glucose output. doi:10.4021/jmc143w